Table 2 Summary of results according to GRADE

Desensitization

1120 (7 RCTs)

2.11 (1.72–2.58)

Two-hundred thirty-eight more per 1000 (154 more to 339 more)

High

Local adverse reaction

1393 (7 RCTs)

1.63 (1.10–2.41)

One-hundred forty-seven more per 1000 (23 more to 330)

Low^a

Systemic adverse reaction

1305 (6 RCTs)

1.52 (1.01–2.28)

Twenty-six more per 1000 (0 fewer to 63 more)

High

Epinephrine utilization

1150 (5 RCTs)

1.62 (0.86–3.04)

Twenty-one more per 1000 (5 fewer to 71 more)

Moderate^c

Topical medication utilization

873 (4 RCTs)

1.39 (1.13–1.71)

One-hundred fifty-four more per 1000 (51 more to 281 more)

High

Serious adverse reaction

1544 (8 RCTs)

1.10 (0.45–2.67)

Three more per 1000 (15 fewer to 45 more)

Low^c,d

Respiratory/ENT

757 (4 RCTs)

0.96 (0.79–1.15)

Eleven fewer per 1000 (58 fewer to 42 more)

Moderate^c

Gastrointestinal disorders

400 (3 RCTs)

1.19 (0.76–1.86)

Seventy-one more per 1000 (90 fewer to 322 more)

Moderate^c

Eye disorders

739 (3 RCTs)

1.02 (0.57–1.81)

One more per 1000 (27 fewer to 50 more)

Moderate^c

Immune system disorders

719 (2 RCTs)

2.13 (0.78–5.81)

One-hundred twenty-four more per 1000 (24 fewer to 530 more)

Moderate^c

Psychiatric disorders

377 (2 RCTs)

0.76 (0.24–2.44)

Six fewer per 1000 (19 fewer to 35 more)

Moderate^c